Cancer, Gene Therapy Top US FDA’s Second Half 2024 User Fee Calendar

 
• By Bridget Silverman
  
T cell and pipette
Cancer is poised to remain the dominate approval category in 2024. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers